Literature DB >> 7679482

Regression of experimental iris neovascularization with systemic alpha-interferon.

J W Miller1, W G Stinson, J Folkman.   

Abstract

BACKGROUND: Intraocular neovascularization leads to visual loss in many eye diseases, including diabetic retinopathy, age-related macular degeneration, and neovascular glaucoma. Current treatment relies on laser photocoagulation, involving the destruction of functional retinal tissue. A pharmacologic treatment directed at the newly growing vessels would represent a major advance.
METHODS: The authors investigated the effect of systemic alpha-interferon in an experimental model of iris neovascularization in cynomolgus monkeys. Alpha-interferon was administered systemically to animals with angiographically documented iris neovascularization.
RESULTS: Animals in the treatment group showed regression of neovascularization angiographically and histologically in eight of eight eyes. Control animals with documented iris neovascularization, followed without drug treatment, showed progression of the neovascularization in three of three eyes.
CONCLUSION: Systemic alpha-interferon led to inhibition of neovascularization and regression of new vessels in an experimental model of iris neovascularization. This represents the first successful, controlled treatment of experimental neovascularization in the eye using a systemic drug directed specifically at the neovascular tissue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679482     DOI: 10.1016/s0161-6420(93)31712-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin.

Authors:  K Mori; A Ando; P Gehlbach; D Nesbitt; K Takahashi; D Goldsteen; M Penn; C T Chen; K Mori; M Melia; S Phipps; D Moffat; K Brazzell; G Liau; K H Dixon; P A Campochiaro
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Age-related macular degeneration.

Authors:  Tariq Ayoub; Nishal Patel
Journal:  J R Soc Med       Date:  2009-02       Impact factor: 5.344

3.  Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.

Authors:  J N Kirkpatrick; A D Dick; J V Forrester
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

Review 4.  Alternative therapies in exudative age related macular degeneration.

Authors:  N H Chong; A C Bird
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

Review 5.  Interferon associated retinopathy.

Authors:  S Hayasaka; Y Nagaki; M Matsumoto; S Sato
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

Review 6.  The preclinical evaluation of angiogenesis inhibitors.

Authors:  M S O'Reilly
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 7.  Vascular endothelial growth factor and ocular neovascularization.

Authors:  J W Miller
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

8.  Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.

Authors:  N Okamoto; T Tobe; S F Hackett; H Ozaki; M A Vinores; W LaRochelle; D J Zack; P A Campochiaro
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

9.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

Review 10.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.